Literature DB >> 26031917

Promising therapies in multiple myeloma.

Giada Bianchi1, Paul G Richardson1, Kenneth C Anderson1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26031917      PMCID： PMC4560339          DOI： 10.1182/blood-2015-03-575365

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  106 in total

1.  Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

Authors:  S Colla; P Storti; G Donofrio; K Todoerti; M Bolzoni; M Lazzaretti; M Abeltino; L Ippolito; A Neri; D Ribatti; V Rizzoli; E Martella; N Giuliani
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

2.  Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Authors:  A Ray; D S Das; Y Song; P Richardson; N C Munshi; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2015-01-30       Impact factor: 11.528

3.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

4.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Authors:  Noopur Raje; Shaji Kumar; Teru Hideshima; Aldo Roccaro; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Dharminder Chauhan; Nikhil C Munshi; Simon R Green; Kenneth C Anderson
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

5.  A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

Authors:  Dharminder Chauhan; Ajita V Singh; Monette Aujay; Christopher J Kirk; Madhavi Bandi; Bryan Ciccarelli; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-08-30       Impact factor: 22.113

6.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

7.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

8.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors:  Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2007-09-28       Impact factor: 22.113

Review 9.  Current strategies for treatment of relapsed/refractory multiple myeloma.

Authors:  Jacob P Laubach; Peter M Voorhees; Hani Hassoun; Andrzej Jakubowiak; Sagar Lonial; Paul G Richardson
Journal:  Expert Rev Hematol       Date:  2014-01-29       Impact factor: 2.929

10.  Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

Authors:  Shaji K Kumar; Betsy LaPlant; Wee Joo Chng; Jeffrey Zonder; Natalie Callander; Rafael Fonseca; Briant Fruth; Vivek Roy; Charles Erlichman; A Keith Stewart
Journal:  Blood       Date:  2014-11-13       Impact factor: 25.476
View more
  36 in total

Review 1.  Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors:  Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2017-06-13

2.  Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

Authors:  A P Nair; P Walker; A Kalff; K Bergin; J Hocking; S Avery; D J Curtis; S Patil; T Das; D Klarica; S Morgan; J Muirhead; M Gorniak; J Reynolds; A Spencer
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

3.  Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma.

Authors:  S Wuillème; A Lok; N Robillard; P Dupuis; V Stocco; H Migné; A Dusquesne; C Touzeau; M Tiab; M C Béné; P Moreau
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

4.  Should minimal residual disease negativity be the end point of myeloma therapy?

Authors:  Kenneth C Anderson
Journal:  Blood Adv       Date:  2017-03-14

5.  The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.

Authors:  Pradeep Bangalore-Prakash; Laura L Stunz; Nurbek Mambetsariev; Amy L Whillock; Bruce S Hostager; Gail A Bishop
Journal:  Blood Adv       Date:  2017-12-18

6.  Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules.

Authors:  Raman Kumar; Nidhi Gupta; Alpana Sharma
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

7.  MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Authors:  Jihane Khalife; Jayeeta Ghose; Marianna Martella; Domenico Viola; Alberto Rocci; Estelle Troadec; Cesar Terrazas; Abhay R Satoskar; Emine Gulsen Gunes; Ada Dona; James F Sanchez; P Leif Bergsagel; Marta Chesi; Alex Pozhitkov; Steven Rosen; Guido Marcucci; Jonathan J Keats; Craig C Hofmeister; Amrita Krishnan; Enrico Caserta; Flavia Pichiorri
Journal:  JCI Insight       Date:  2019-11-01

8.  Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.

Authors:  Jia Tong; Qing Yu; Wenbin Xu; Wenjun Yu; Chao Wu; Yingli Wu; Hua Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

Review 9.  Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

Authors:  Nagaraju Anreddy; Lori A Hazlehurst
Journal:  J Cell Biochem       Date:  2016-06-21       Impact factor: 4.429

10.  Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.

Authors:  Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim
Journal:  Bone Marrow Transplant       Date:  2020-01-28       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.